Judicial Invalidation of the FDA’s Laboratory-Developed Test Rule — Legal and Public Health Consequences
R
Rachel E. Sachs
(Washington University in St. Louis School of Law, St. Louis)
J
Joshua M. Sharfstein
(Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore)
P
Patricia J. Zettler
(Ohio State University, Columbus)
Article Details
Journal
New England Journal of Medicine
Volume / Issue
Vol. 392, Issue 20
Published
May 29, 2025
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
ISSN: 0028-4793 Social Sciences
Authors (3)
R
Rachel E. Sachs
Washington University in St. Louis School of Law, St. Louis
J
Joshua M. Sharfstein
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore
P
Patricia J. Zettler
Ohio State University, Columbus
Related Articles from this Journal
Doctor’s Dirty Little Secret — The Cost of Silence
Tara Khan
Aug 2026
10.1056/nejmp2515506
Obstructive Hypertrophic Cardiomyopathy
Julian-Kai Nishizono, Marohito Nakata
Aug 2026
10.1056/nejmicm2603868
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Martina Schatzl, Katharina A. Mayer et al.
Jul 2026
10.1056/nejmc2603853
Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
Jerry Avorn
Jul 2026
10.1056/nejmp2604841
Precision Intensification in Metastatic Prostate Cancer
Rana R. McKay
Jul 2026
10.1056/nejme2605582